Lung Cancer Trials Ask AI to find trials
CompletedPhase 3NCT00364351
Official study title

Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

Study summary

To determine if ZD6474 a new investigational drug, is effective in treating Non Small Lung Cancer and if so, how it compares with another type of anti cancer therapy chemotherapy, Erlotinib

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedVandetanib and Erlotinib

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 25, 2018 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 3

Interventional

Where is it offered?153 U.S. locations

Locations may change over time.

Who runs it?Genzyme, a Sanofi Company

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 3
Sponsor
Genzyme, a Sanofi Company
Interventions being studied
Drug: Vandetanib; Drug: Erlotinib
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Confirmed locally advanced or metastatic NSCLC
  • Failure of at least one but not more than two prior chemotherapy regimens
Reasons someone may not be able to joinExclusion criteria
  • Prior treatment with erlotinib (Tarceva), gefitinib (IRESSA), sunitinib (Sutent), sorafenib (Nexavar)
  • Chemotherapy or other type of anti cancer therapy within 4 weeks of study start

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Research SiteBerkeley, California
  • Research SiteLos Angeles, California
  • Research SiteSanta Rosa, California
  • Research SiteBoynton Beach, Florida
  • Research SiteFort Myers, Florida
  • Research SiteJacksonville, Florida
  • Research SitePort Saint Lucie, Florida
  • Research SiteWichita, Kansas
  • Research SiteLexington, Kentucky
  • Research SiteLouisville, Kentucky
  • Research SiteMetairie, Louisiana
  • Research SiteBaltimore, Maryland

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 25, 2018. Always confirm current availability with the study team.

View original record ↗